You are here

Fast Track Designation Granted for Cloretazine in Elderly Poor-Risk Acute Myelogenous Leukemia

NEW HAVEN, Conn., Oct. 17 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (NASDAQ:VION) announced today that it had received Fast Track designation from the U.S. Food and Drug Administration ("FDA") for its anticancer agent Cloretazine(R) for induction treatment of patients over 60 years of age with poor-risk acute myelogenous leukemia ("AML"). This is the second indication for which Cloretazine(R) has received a Fast Track designation.

Under the FDA Modernization Act of 1997, Fast Track designation allows the FDA to accept, on a rolling basis, portions of a marketing application prior to the completion of the final registration package. Fast Track designation may potentially expedite the review of a drug that is intended for the treatment of a serious life-threatening condition and demonstrates the potential to address an unmet medical need for such a condition.

Alan Kessman, Chief Executive Officer, stated, "We are pleased that the FDA has granted an additional fast track designation to Cloretazine(R). Based on our Phase II data in this indication, we believe that Cloretazine(R) has potential for the treatment of this unmet medical need. We look forward to meeting with the FDA to discuss the specifics of the path forward."

Source: Vion Pharmaceuticals, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs